102 related articles for article (PubMed ID: 23108910)
1. Tumour burden at diagnosis as the main clinical predictor of cell resistance in patients with early stage, favourable Hodgkin lymphoma treated with VBM chemotherapy plus radiotherapy.
Gobbi PG; Bergonzi M; Bassi E; Merli F; Coriani C; Federico M
Hematol Oncol; 2013 Sep; 31(3):151-5. PubMed ID: 23108910
[TBL] [Abstract][Full Text] [Related]
2. Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy.
Gobbi PG; Bassi E; Bergonzi M; Merli F; Coriani C; Iannitto E; Luminari S; Polimeno G; Federico M
Hematol Oncol; 2012 Dec; 30(4):194-9. PubMed ID: 22271092
[TBL] [Abstract][Full Text] [Related]
3. Vinblastine, bleomycin, and methotrexate chemotherapy plus irradiation for patients with early-stage, favorable Hodgkin lymphoma: the experience of the Gruppo Italiano Studio Linfomi.
Gobbi PG; Broglia C; Merli F; Dell'Olio M; Stelitano C; Iannitto E; Federico M; Bertè R; Luisi D; Molica S; Cavalli C; Dezza L; Ascari E
Cancer; 2003 Dec; 98(11):2393-401. PubMed ID: 14635074
[TBL] [Abstract][Full Text] [Related]
4. Chemoresistance as a function of the pretherapy tumor burden and the chemotherapy regimen administered: differences observed with 2 current chemotherapy regimens for advanced Hodgkin lymphoma.
Gobbi PG; Valentino F; Bassi E; Coriani C; Merli F; Bonfante V; Marchianò A; Gallamini A; Bolis S; Stelitano C; Levis A; Federico M; Angrilli F; Di Giulio G; Corazza GR
Clin Lymphoma Myeloma Leuk; 2011 Oct; 11(5):396-402. PubMed ID: 21729691
[TBL] [Abstract][Full Text] [Related]
5. Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial.
Iannitto E; Minardi V; Gobbi PG; Calvaruso G; Tripodo C; Marcheselli L; Luminari S; Merli F; Baldini L; Stelitano C; Callea V; Petrini M; Angrilli F; Quarta G; Vallisa D; Molica S; Liardo E; Polimeno G; Brugiatelli M; Federico M
Clin Lymphoma Myeloma; 2009 Apr; 9(2):138-44. PubMed ID: 19406724
[TBL] [Abstract][Full Text] [Related]
6. Vinblastine, bleomycin, and methotrexate chemotherapy plus extended-field radiotherapy in early, favorably presenting, clinically staged Hodgkin's patients: the Gruppo Italiano per lo Studio dei Linfomi Experience.
Gobbi PG; Pieresca C; Frassoldati A; Carotenuto M; Di Renzo N; La Sala A; Berté R; Avanzini P; Federico M; Silingardi V; Ascari E
J Clin Oncol; 1996 Feb; 14(2):527-33. PubMed ID: 8636767
[TBL] [Abstract][Full Text] [Related]
7. Tumor burden in Hodgkin's lymphoma can be reliably estimated from a few staging parameters.
Gobbi PG; Bergonzi M; Bassi E; Merli F; Coriani C; Stelitano C; Iannitto E; Federico M
Oncol Rep; 2012 Sep; 28(3):815-20. PubMed ID: 22752083
[TBL] [Abstract][Full Text] [Related]
8. What has happened to VBM (vinblastine, bleomycin, and methotrexate) chemotherapy for early-stage Hodgkin lymphoma?
Gobbi PG; Federico M
Crit Rev Oncol Hematol; 2012 Apr; 82(1):18-24. PubMed ID: 21592816
[TBL] [Abstract][Full Text] [Related]
9. Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy.
Shankar A; Hayward J; Kirkwood A; McCarthy K; Hewitt M; Morland B; Daw S
Br J Haematol; 2014 May; 165(4):534-44. PubMed ID: 24754633
[TBL] [Abstract][Full Text] [Related]
10. [Our experiences in treating patients with Hodgkin disease in the last decade].
Simon Z; Keresztes K; Miltényi Z; Ress Z; Váróczy L; Vadász G; Gergely L; Illés A
Orv Hetil; 2007 Apr; 148(15):675-82. PubMed ID: 17416575
[TBL] [Abstract][Full Text] [Related]
11. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
12. Results of radiotherapy and combined modality treatment in early stage high grade non-Hodgkin's lymphoma.
Frank C; Flentje M; Goldschmidt H; Hunstein W; Wannenmacher M
Strahlenther Onkol; 1994 Jul; 170(7):383-90. PubMed ID: 8052937
[TBL] [Abstract][Full Text] [Related]
13. Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma.
Vassilakopoulos TP; Angelopoulou MK; Siakantaris MP; Kontopidou FN; Dimopoulou MN; Kokoris SI; Kyrtsonis MC; Tsaftaridis P; Karkantaris C; Anargyrou K; Boutsis DE; Variamis E; Michalopoulos T; Boussiotis VA; Panayiotidis P; Papavassiliou C; Pangalis GA
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):765-81. PubMed ID: 15183480
[TBL] [Abstract][Full Text] [Related]
14. The clinical value of tumor burden at diagnosis in Hodgkin lymphoma.
Gobbi PG; Broglia C; Di Giulio G; Mantelli M; Anselmo P; Merli F; Zinzani PL; Rossi G; Callea V; Iannitto E; Paulli M; Garioni L; Ascari E
Cancer; 2004 Oct; 101(8):1824-34. PubMed ID: 15372482
[TBL] [Abstract][Full Text] [Related]
15. Risk-adapted therapy with three or six cycles of doxorubicin/bleomycin/vinblastine/dacarbazine plus involved-field radiation therapy in Hodgkin lymphoma, based on prognosis at diagnosis and early response: results from the GATLA study.
Pavlovsky S; Corrado C; Pavlovsky MA; Prates MV; Zoppegno L; Giunta M; Cerutti I; Palomino E; Pagani F; Lastiri F; Bar D; Bezares RF; Avila G
Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):181-5. PubMed ID: 20511162
[TBL] [Abstract][Full Text] [Related]
16. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
[TBL] [Abstract][Full Text] [Related]
17. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
[TBL] [Abstract][Full Text] [Related]
18. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma.
Kobe C; Kuhnert G; Kahraman D; Haverkamp H; Eich HT; Franke M; Persigehl T; Klutmann S; Amthauer H; Bockisch A; Kluge R; Wolf HH; Maintz D; Fuchs M; Borchmann P; Diehl V; Drzezga A; Engert A; Dietlein M
J Clin Oncol; 2014 Jun; 32(17):1776-81. PubMed ID: 24799482
[TBL] [Abstract][Full Text] [Related]
19. [Treatment option and outcome for patients with primary non-Hodgkin's lymphoma of the nasal cavity].
Yao B; Li YX; Song YW; Jin J; Liu YP; Wang WH; Wang SL; Sun YT; Yu ZH; Liu XF
Zhonghua Zhong Liu Za Zhi; 2006 Jan; 28(1):58-61. PubMed ID: 16737624
[TBL] [Abstract][Full Text] [Related]
20. A randomized trial of brief treatment of early- stage Hodgkin lymphoma: Is it effective?
Hamed RH; Anter AH; Awad IA
Hematol Oncol Stem Cell Ther; 2012; 5(1):36-41. PubMed ID: 22446609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
